ArticleCell reports. Medicine2022
Proteomic and functional characterization of intra-tumor heterogeneity in human endometrial cancer.
Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Artificial intelligence-driven integration of multi-biofluid omics and clinical phenotype enables stratification of endometrial cancer.Cell reports. Medicine · 2026Article
- Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026Review
- USP26-mediated stabilization of RAD51 promotes endometrial cancer progression and limits ferroptosis.Frontiers in oncology · 2026Article
- Epigenetics of Endometrial Cancer: The Role of Chromatin Modifications and Medicolegal Implications.International journal of molecular sciences · 2025Review
- Present progress in biomarker discovery of endometrial cancer by multi-omics approaches.Clinical proteomics · 2025Review
- FBXO31-mediated ubiquitination of OGT maintains O-GlcNAcylation homeostasis to restrain endometrial malignancy.Nature communications · 2025Article
- Review
- Topological embedding and directional feature importance in ensemble classifiers for multi-class classification.Computational and structural biotechnology journal · 2024Article
- Glycolysis-mTORC1 crosstalk drives proliferation of patient-derived endometrial cancer spheroid cells with ALDH activity.Cell death discovery · 2024Article
- Organoid modeling meets cancers of female reproductive tract.Cell death discovery · 2024Review
- The use of organoids in creating immune microenvironments and treating gynecological tumors.Journal of translational medicine · 2024Review
- Article
- Bioengineering approaches for the endometrial research and application.Materials today. Bio · 2024Review
- Research progress on the application of organoids in gynecological tumors.Frontiers in pharmacology · 2024Review
- Development of a long term, ex vivo, patient-derived explant model of endometrial cancer.PloS one · 2024Article
- Integrating proteomics and explainable artificial intelligence: a comprehensive analysis of protein biomarkers for endometrial cancer diagnosis and prognosis.Frontiers in molecular biosciences · 2024Article
- Addressing Key Questions in Organoid Models: Who, Where, How, and Why?International journal of molecular sciences · 2023Review
- Article
- Closer to the Reality-Proteome Changes Evoked by Endometrial Scratching in Fertile Females.International journal of molecular sciences · 2023Article
- Upgrading Treatment and Molecular Diagnosis in Endometrial Cancer-Driving New Tools for Endometrial Preservation?International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is one of the most frequently diagnosed gynecological cancers worldwide, and its prevalence has increased by more than 50% over the last two decades. Despite the understanding of the major signaling pathways driving the growth and metastasis of endometrial cancer, clinical trials targeting these signals have reported poor outcomes. The heterogeneous nature of endometrial cancer is suspected to be one of the key reasons for the failure of targeted therapies. In this study, we perform a sequential window acquisition of all theoretical fragment ion spectra (SWATH)-based comparative proteomic analysis of 63 tumor biopsies collected from 20 patients and define differences in protein signature in multiple regions of the same tumor. We develop organoids from multiple biopsies collected from the same tumor and show that organoids capture heterogeneity in endometrial cancer growth. Overall, using quantitative proteomics and patient-derived organoids, we define the heterogeneous nature of endometrial cancer within a patient's tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.